Goldman Sachs on Ultragenyx Pharma (RARE): 'we remain constructive'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $78.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
